Sugentech Inc (253840) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sugentech Inc (253840) has a cash flow conversion efficiency ratio of -0.037x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.86 Billion ≈ $-1.94 Million USD) by net assets (₩76.54 Billion ≈ $51.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sugentech Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Sugentech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sugentech Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Sugentech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sugentech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TPL Plastech Limited
NSE:TPLPLASTEH
|
0.277x |
|
Nido Education Ltd
AU:NDO
|
0.049x |
|
Cayson Acquisition Corp Ordinary shares
NASDAQ:CAPN
|
0.000x |
|
CTI Traffic Industries Co Ltd
TWO:2230
|
-0.134x |
|
Nila Spaces Limited
NSE:NILASPACES
|
-0.018x |
|
Woory Industrial Co. Ltd
KQ:215360
|
0.034x |
|
Hwacheon Mac
KO:000850
|
0.007x |
|
Hankook Furniture Co. Ltd
KQ:004590
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Sugentech Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Sugentech Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 253840 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩76.54 Billion ≈ $51.87 Million |
₩-14.65 Billion ≈ $-9.93 Million |
-0.191x | -147.24% |
| 2024-12-31 | ₩97.13 Billion ≈ $65.82 Million |
₩-7.52 Billion ≈ $-5.09 Million |
-0.077x | +28.39% |
| 2023-12-31 | ₩112.45 Billion ≈ $76.21 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.108x | -149.93% |
| 2022-12-31 | ₩140.58 Billion ≈ $95.27 Million |
₩30.43 Billion ≈ $20.62 Million |
0.216x | -44.04% |
| 2021-12-31 | ₩100.71 Billion ≈ $68.25 Million |
₩38.96 Billion ≈ $26.40 Million |
0.387x | +67.51% |
| 2020-12-31 | ₩63.11 Billion ≈ $42.77 Million |
₩14.57 Billion ≈ $9.87 Million |
0.231x | +239.92% |
| 2019-12-31 | ₩24.31 Billion ≈ $16.47 Million |
₩-4.01 Billion ≈ $-2.72 Million |
-0.165x | +18.61% |
| 2018-12-31 | ₩15.46 Billion ≈ $10.47 Million |
₩-3.13 Billion ≈ $-2.12 Million |
-0.203x | -831.42% |
| 2017-12-31 | ₩-32.81 Billion ≈ $-22.24 Million |
₩-909.59 Million ≈ $-616.42K |
0.028x | -- |
About Sugentech Inc
Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more